The stock of Fibrocell Science Inc (NASDAQ:FCSC) hit a new 52-week high and has GBX 1.18 target or 44.00% above today’s GBX 0.82 share price. The 7 months bullish chart indicates low risk for the GBX 36.26 million company. The 1-year high was reported on Sep, 14 by Barchart.com. If the GBX 1.18 price target is reached, the company will be worth GBX 15.95M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock decreased 6.09% or $0.053 on September 13, hitting $0.822. About 96,872 shares traded hands. Fibrocell Science Inc (NASDAQ:FCSC) has declined 59.91% since February 8, 2016 and is downtrending. It has underperformed by 76.40% the S&P500.
Out of 3 analysts covering Fibrocell Science (NASDAQ:FCSC), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Fibrocell Science has been the topic of 3 analyst reports since September 28, 2015 according to StockzIntelligence Inc. Roth Capital initiated the stock on December 22 with “Buy” rating.
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has a market cap of $36.26 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.